Coherus Reports the US FDA’s Acceptance of BLA for CHS-1420 (biosimilar, adalimumab)

 Coherus Reports the US FDA’s Acceptance of BLA for CHS-1420 (biosimilar, adalimumab)

Coherus Reports the US FDA’s Acceptance of BLA for CHS-1420 (biosimilar, adalimumab)

Shots:

  • The US FDA has accepted the BLA under the 351(k) for CHS-1420 with an anticipated BsUFA date as Dec’2021
  • The company plans to launch the CHS-1420 in the US on or after Jul 01, 2023 as per the terms of an agreement with AbbVie
  • Coherus collaborated with Junshi in Feb’2021 to in-license toripalimab in the US and Canada. Additionally, Coherus will market Udenyca (pegfilgrastim) in the US and plans to launch biosimilars of Humira, Avastin and Lucentis in 2023, following their approval

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Coherus

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post